NeoGenomics
NeoGenomics Laboratories operates a network of cancer-focused testing facilities in the United States, Switzerland, and Singapore. The company is divided into two main segments: Clinical Services and Pharma Services. It provides a range of genetic and molecular testing services, including cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing, aimed at helping clinicians and researchers understand cancer at a genetic level. Additionally, NeoGenomics offers morphologic analysis for diagnosis and supports pharmaceutical companies in their oncology programs through testing services that facilitate drug development and clinical trials. The company's collaboration with Inivata Limited for the commercialization of the InVisionFirst-Lung liquid biopsy test exemplifies its commitment to advancing cancer diagnostics. Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics serves hospitals, pathologists, oncologists, academic centers, and other clinical laboratories, enhancing cancer care through innovative testing solutions.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
8 past transactions
Inivata
Acquisition in 2021
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.
Trapelo Health
Acquisition in 2021
Trapelo Health is a healthcare technology company based in Cambridge, Massachusetts, that specializes in precision oncology. Founded in 2009, the company has developed a collaborative decision support platform that provides evidence-based reports in molecular oncology for physicians, payers, and labs. This platform facilitates the alignment of molecular test results with associated therapies, enabling healthcare providers to efficiently identify appropriate treatments based on the latest medical evidence. Trapelo Health aims to enhance the use of precision medicine by fostering collaboration among oncologists, molecular labs, and payers, ultimately supporting effective cancer care through the analysis of cancerous tissues and the generation of genomic insights.
Inivata
Corporate Round in 2020
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.
Human Longevity - Oncology Division
Acquisition in 2020
Oncology Division performs genome sequencing services for pharmaceutical customers including germline and whole exome sequencing.
Genoptix
Acquisition in 2018
Genoptix, Inc. is a specialized provider of oncology diagnostics services, focusing on delivering comprehensive testing solutions for hematologic malignancies and solid tumors. The company offers a variety of services, including customizable clinical trial support, custom assay development, and companion diagnostics. Its diagnostic capabilities encompass chromogenic and fluorescent immunohistochemistry, cytogenetics, flow cytometry, and a range of molecular testing platforms. Genoptix performs specialty assays to aid in patient diagnosis, treatment stratification, and disease monitoring, while also providing professional services for study data interpretation and endpoint adjudication. The company collaborates with community oncologists and pathologists to enhance molecular profiling in oncology and has established a strategic alliance with Bionano Genomics. Founded in 1999 and headquartered in Carlsbad, California, Genoptix is committed to advancing cancer diagnostics and improving patient outcomes through innovative testing solutions.
Clarient
Acquisition in 2015
Clarient is a prominent provider of cancer diagnostic testing services, specializing in anatomic pathology and molecular testing. The company collaborates with local pathologists and oncologists to enhance the standard of care within their communities. By employing advanced technologies, Clarient assists healthcare professionals in accurately diagnosing cancer cases and provides valuable insights into effective therapies for patients. Additionally, the company offers consultative and commercial services tailored to biopharmaceutical companies and research organizations, as well as hematopathology testing specifically for leukemia and lymphoma. Through its comprehensive offerings, Clarient is committed to delivering clarity in complex diagnostic challenges and ensuring ongoing case monitoring and follow-up.
Path Logic
Acquisition in 2014
Path Logic, Inc. is an anatomic pathology services provider based in Sacramento, California, serving clients primarily in the western United States. The company specializes in various subspecialties of pathology, including dermatopathology, nephropathology, gastrointestinal pathology, genitourinary pathology, hematopathology, and women's health. Additionally, Path Logic offers molecular diagnostics and hospital services, which include inpatient pathology services and medical lab directorship. The company's laboratory services encompass slide preparation, immunohistochemistry, special stains, liquid-based cytology, electron microscopy, and immunofluorescence microscopy. Renowned for its commitment to accurate diagnostics and rapid turnaround times for patient results, Path Logic prioritizes personalized customer service and facilitates web-based information sharing to enhance its service delivery.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.